Crinetics Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Crinetics Pharmaceuticals, Inc. (CRNX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $104.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- Crinetics Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $104.00K.
- Crinetics Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$7.39M, a 690.65% decline from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $1.25M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $104.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | -$7.39M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.25M 10-K · filed 2026-02-26 |